Isofol Medical: Key parameters of study design accepted by FDA
Research Note
2018-01-17
10:58
Isofol Medical reported that the company has had a successful meeting with the FDA concerning the planned phase III trial in colorectal cancer. The FDA has accepted key parameters of the study design and confirmed that they will accept a successful trial outcome as support for market approval of Modufolin.
AN
Arvid Necander
Disclosures and disclaimers